[Fibrin pleurodesis in malignant pleural effusions].
Fibrin pleurodesis was performed on 30 patients with malignant pleural effusions. A pleural catheter was inserted to empty the pleural space and effect the pleurodesis. When the pleural space was dry, 20 000 U of aprotinin were instilled intrapleurally for local fibrinolysis inhibition. 10 ml fibrinogen concentrate and 10 ml thrombin (500 U/ml) and 3000 KI U/ml aprotinin were then applied. Complete success was achieved in 19 of 27 patients, partial success in two. The results could not be evaluated in three patients. The only side-effect of the treatment was a subfebrile temperature in three of the 30 patients. Fibrin pleurodesis thus proved itself as an effective form of treatment with few side-effects (10%).
E D
ED
Kreuser
E
E
Seifried
U
U
Harsch
B
B
Brass
W
W
Schreml
H
H
Heimpel
D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D007611:Aprotinin / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000150:complications; D002283:Carcinoma, Bronchogenic / Q000150:complications; D002292:Carcinoma, Renal Cell / Q000150:complications; D004322:Drainage; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010994:Pleura; D010996:Pleural Effusion / Q000209:etiology* / Q000628:therapy; D011187:Posture; D011379:Prognosis; D013917:Thrombin / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D005340:Fibrinogen; D006493:Heparin; D007611:Aprotinin; D013917:Thrombin
Fibrinpleurodese bei malignen Pleuraergüssen.